Manager TitleAgeSince
Chief Executive Officer 53 2022-08-29
Director of Finance/CFO 55 2023-05-01
Chief Tech/Sci/R&D Officer 51 -
Director TitleAgeSince
Director/Board Member 53 2015-08-31
Chairman 71 2021-04-14
Director/Board Member 59 2021-04-14
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.51M
-0.48%+7.20%-5.65%+3.69% 46.2B
+2.19%+11.71%+393.31%+609.31% 38.71B
+2.53%+13.93%+21.38%-10.96% 31.9B
+1.65%+3.61%+16.04%+55.24% 31.12B
-4.16%-2.58%+8.94%+26.14% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+69.64%+136.34% 15.05B
+1.00%+10.30%+13.31%+23.36% 13.74B
+3.63%+9.53%+103.97%+106.25% 13.42B
Average +0.74%+9.14%+77.62%+118.67% 25.57B
Weighted average by Cap. +0.75%+8.71%+88.75%+138.12%
Logo Amniotics AB
Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
Employees
4